MedBulletinsAura Celeste
Orthopedics

What's next in orthopedics — November 15, 2026

🎧 Listen to this issueAudio newscast · 4:17 min

This edition covers what arrives between late December 2026 and early March 2027. Four items: two regulatory topics with three FDA target action dates (postoperative analgesia and achondroplasia), plus the ORS and AAOS meetings, which open the orthopedic year. Programs that failed in phase 3 during 2026 or lack a verifiable date were left out; none of what follows changes practice yet.

1. Fast-acting meloxicam for postoperative pain

[Pending regulatory decision] [United States] [PDUFA goal date: December 27, 2026]
What it is: A Viatris new drug application (505(b)(2) pathway) for MR-107A-02, a fast-acting oral meloxicam, in moderate-to-severe acute pain, with a PDUFA goal date of December 27, 2026, according to Viatris. It rests on two randomized, double-blind phase 3 trials controlled with placebo and with tramadol 50 mg every 6 h as active control: bunionectomy (NCT06215820, 410 randomized patients) and herniorrhaphy (NCT06215859, 579 randomized patients); primary endpoint SPID 0–48 h.
What problem it solves: Reducing opioid use in the immediate postoperative period after outpatient orthopedic surgery such as forefoot procedures; today we use multimodal analgesia (NSAIDs, acetaminophen, regional blocks) with rescue opioids.
Critical take: Company-sponsored trials; the company reports endpoints met and a "significant reduction" in opioids, but the May acceptance announcement does not quantify the effects on pain and opioid use. There is no head-to-head comparison with a well-dosed generic NSAID, and the class's renal, gastrointestinal and cardiovascular risks remain.

Sources

2. Achondroplasia: oral infigratinib and full approval of vosoritide

[Pending regulatory decision] [United States] [PDUFA target action date: February 4, 2027]
What it is: The FDA accepted, with priority review, BridgeBio's application for oral infigratinib (an FGFR3 inhibitor) in children with achondroplasia, with a PDUFA target action date of February 4, 2027, according to BridgeBio; the application is based on the double-blind, placebo-controlled phase 3 PROPEL 3 trial (NCT06164951): at 52 weeks, difference in annualized height velocity of +1.74 cm/year (least-squares mean; observed mean difference +2.10 cm/year; p<0.0001). In addition, the application to convert vosoritide to full approval has a PDUFA target action date of February 28, 2027, according to BioMarin; vosoritide currently holds accelerated approval in the US, and the application rests on long-term data from three ongoing studies. BridgeBio has already submitted its marketing authorization application to the EMA, which is now under review, according to its third-quarter 2026 report.
What problem it solves: In the US there are now two approved targeted therapies, both injectable and both under accelerated approval: vosoritide, a daily subcutaneous injection, and navepegritide (Ascendis Pharma), once weekly, approved on February 27, 2026; an oral option could ease adherence. For pediatric orthopedics, the question is whether it changes the course of foramen magnum and lumbar stenosis, genu varum and limb-lengthening surgery.
Critical take: Height velocity is a surrogate endpoint; for infigratinib there are no final-height data or data on fewer orthopedic complications or operations, the proportionality improvement was exploratory (children aged 3 to 8), and access and cost in our setting are uncertain.

Sources

3. Orthopaedic Research Society Annual Meeting (ORS 2027)

[Congress] [United States] [Confirmed date: February 19, 2027]
What it is: The ORS annual meeting, February 19–23, 2027, at Moscone West in San Francisco; the leading forum for basic and translational research in bone, cartilage, tendon and spine.
What problem it solves: Knee osteoarthritis still has no disease-modifying drug: on September 23, 2026, the phase 3 PARA_OA_012 trial (injectable pentosan polysulfate from Paradigm Biopharmaceuticals, 538 patients treated; NCT06917404) was stopped for futility at the interim analysis. Management remains exercise, weight control, analgesics, injections and arthroplasty.
Critical take: Most of what is presented is preclinical or early phase; useful for trends, not for changing practice.

Sources

4. AAOS 2027 Annual Meeting

[Congress] [United States] [Confirmed date: March 3, 2027]
What it is: The annual meeting of the American Academy of Orthopaedic Surgeons, March 3–6, 2027, at the Venetian Convention & Expo Center in Las Vegas.
What problem it solves: It is the main showcase for clinical evidence in orthopedics, arthroplasty registry data and updates to AAOS guidelines and appropriate use criteria (in June 2026 the AAOS Board of Directors approved the ankle osteoarthritis guideline and the rotator cuff pathology appropriate use criteria).
Critical take: A substantial share of presented abstracts never reach peer-reviewed publication; wait for the paper before changing practice.

Sources

Get every issue by email

Free. One email with each new issue, with a short summary and links to the page and the audio. No ads inside the content: any sponsor is identified and has no say in the selection. We do not share your data; unsubscribe with a single message.